-Reuters
Kymera Therapeutics Stock Jumps After Positive Data From Atopic Dermatitis Trial
Kymera Therapeutics Inc (NASDAQ:KYMR) announced clinical results from the patient cohort portion of its KT-474 (IRAK4) Phase 1 trial in hidradenitis…
Related Posts
5 Value Stocks To Watch In The Financial Services Sector
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the…
$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today
Pacific Biosciences (NASDAQ:PACB) has outperformed the market over the past 5 years by 3.38% on an annualized basis producing an average annual return of 15.27%. Currently, Pacific Biosciences has a market capitalization of $1.89 billion.
Binance’s Congestion Cataclysm: Bitcoin, Ether, PEPE, And SUI Caught In The Crossfire
Bitcoin (CRYPTO: BTC) value declined Monday on the heels of a weekend slump, as one of the largest global crypto exchanges reported congestion